Regeneron Melanoma Trial: -11.5% Plunge After Phase 3 Shock
Can the Regeneron Melanoma Trial setback derail the biotech’s oncology growth story, or will upcoming data flip the narrative? Maik Kemper Editor in Chief Conclusion Against a backdrop…
Can the Regeneron Melanoma Trial setback derail the biotech’s oncology growth story, or will upcoming data flip the narrative? Maik Kemper Editor in Chief Conclusion Against a backdrop…